This is a randomized, open-label, multicenter, parallel-group safety study in naive hepatitis C patients. Total of 40 subjects will be enrolled and will receive either 9 mcg of infergen daily or 9 mcg of infergen plus 1200/1000mg of ribavirin daily. Non-genotype I patients receiving combination therapy will be treated for 24 weeks. Genotype I patients will be treated for 48 weeks. Subjects completing treatment III will be followed for an additional 24 weeks to assess presence of sustained viral response. Primary endpoint is to assess the 12 week safety and tolerability profiles of infegen dministered with ribavirin and infergen in naive, chronic Hep C patient population.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000833-26
Application #
6409346
Study Section
General Clinical Research Centers Committee (CLR)
Project Start
1977-12-01
Project End
2001-02-28
Budget Start
Budget End
Support Year
26
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Winn, Virginia D; Gormley, Matthew; Fisher, Susan J (2011) The Impact of Preeclampsia on Gene Expression at the Maternal-Fetal Interface. Pregnancy Hypertens 1:100-8
Delaney, Joseph A C; Scherzer, Rebecca; Biggs, Mary L et al. (2010) Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness. AIDS 24:2201-9
Pan, Warren W; Li, Jain-Dong; Huang, Shuang et al. (2010) Synergistic activation of NF-{kappa}B by bacterial chemoattractant and TNF{alpha} is mediated by p38 MAPK-dependent RelA acetylation. J Biol Chem 285:34348-54
Huang, XueSong; Chen, Ling-Yu; Doerner, Astrid M et al. (2009) An atypical protein kinase C (PKC zeta) plays a critical role in lipopolysaccharide-activated NF-kappa B in human peripheral blood monocytes and macrophages. J Immunol 182:5810-5
Mukherjee, Sumanta; Chen, Ling-Yu; Papadimos, Thomas J et al. (2009) Lipopolysaccharide-driven Th2 cytokine production in macrophages is regulated by both MyD88 and TRAM. J Biol Chem 284:29391-8
Chen, Ling-Yu; Pan, Zhixing K (2009) Synergistic activation of leukocytes by bacterial chemoattractants: potential drug targets. Endocr Metab Immune Disord Drug Targets 9:361-70
Chen, Ling-Yu; Pan, Warren W; Chen, Miao et al. (2009) Synergistic induction of inflammation by bacterial products lipopolysaccharide and fMLP: an important microbial pathogenic mechanism. J Immunol 182:2518-24
Ito, Tatsuo; Yadav, Neelu; Lee, Jaeho et al. (2009) Arginine methyltransferase CARM1/PRMT4 regulates endochondral ossification. BMC Dev Biol 9:47
Price, Richard W; Parham, Robin; Kroll, Jing Lu et al. (2008) Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther 13:369-74
Dawson, Arthur; Abel, Susan L; Loving, Richard T et al. (2008) CPAP therapy of obstructive sleep apnea in type 2 diabetics improves glycemic control during sleep. J Clin Sleep Med 4:538-42

Showing the most recent 10 out of 871 publications